X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (51) 51
Book Review (6) 6
Patent (6) 6
Conference Proceeding (5) 5
Publication (3) 3
Book Chapter (2) 2
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (30) 30
humans (29) 29
oncology (22) 22
melanoma (19) 19
cancer (18) 18
immunotherapy (16) 16
male (16) 16
female (14) 14
melanoma - drug therapy (13) 13
ipilimumab (12) 12
middle aged (12) 12
aged (11) 11
antibodies, monoclonal - therapeutic use (11) 11
adult (10) 10
immunology (10) 10
metastatic melanoma (9) 9
cancer research (8) 8
care and treatment (8) 8
medicine & public health (8) 8
melanoma - immunology (8) 8
monoclonal antibodies (8) 8
antineoplastic agents - therapeutic use (7) 7
combination (7) 7
drug therapy (7) 7
immunotherapy - methods (7) 7
metastasis (7) 7
antibodies, monoclonal - adverse effects (6) 6
antigens (6) 6
melanoma - pathology (6) 6
neoplasm staging (6) 6
neoplasms - immunology (6) 6
therapy (6) 6
treatment outcome (6) 6
antibodies, monoclonal - administration & dosage (5) 5
clinical trials (5) 5
dna methylation (5) 5
melanoma - mortality (5) 5
research (5) 5
skin neoplasms - drug therapy (5) 5
survival (5) 5
young adult (5) 5
antigens, neoplasm - genetics (4) 4
antineoplastic agents - adverse effects (4) 4
cancer testis antigens (4) 4
cell biology (4) 4
climate change mitigation technologies related to wastewatertreatment or waste management (4) 4
crushing, pulverising, or disintegrating (4) 4
crushing, pulverising, or disintegrating in general (4) 4
ctla-4 (4) 4
ctla-4 antigen - immunology (4) 4
dacarbazine (4) 4
follow-up studies (4) 4
general tagging of cross-sectional technologies spanning over several sections of the ipc (4) 4
general tagging of new technological developments (4) 4
magnetic or electrostatic separation of solid materials from solidmaterials or fluids (4) 4
melanoma - genetics (4) 4
mesothelioma (4) 4
metastases (4) 4
milling grain (4) 4
neoplasm metastasis (4) 4
neoplasms - therapy (4) 4
performing operations (4) 4
phase-ii (4) 4
preparatory treatment of grain for milling (4) 4
prognosis (4) 4
separating solid materials using liquids or using pneumatictables or jigs (4) 4
separation by high-voltage electric fields (4) 4
separation of solid materials using liquids or using pneumatictables or jigs (4) 4
t cells (4) 4
technical subjects covered by former uspc cross-reference art collections [xracs] and digests (4) 4
technologies or applications for mitigation or adaptation againstclimate change (4) 4
transporting (4) 4
tumors (4) 4
animals (3) 3
antibodies (3) 3
antibodies, monoclonal - pharmacology (3) 3
antigens, cd - immunology (3) 3
antineoplastic agents - administration & dosage (3) 3
azacitidine - analogs & derivatives (3) 3
azacitidine - pharmacology (3) 3
cell line, tumor (3) 3
chemotherapy (3) 3
class-i antigens (3) 3
clinical trials as topic (3) 3
complications and side effects (3) 3
ctla-4 antigen - antagonists & inhibitors (3) 3
cytotoxic t-lymphocyte antigen-4 (3) 3
disease-free survival (3) 3
dna methylation - drug effects (3) 3
dosage and administration (3) 3
expression (3) 3
hematology, oncology and palliative medicine (3) 3
human cutaneous melanoma (3) 3
immunogenicity (3) 3
interleukin-2 (3) 3
lymphocytes (3) 3
lymphocytes t (3) 3
medical research (3) 3
medicine, research & experimental (3) 3
mesothelioma - drug therapy (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Nature Medicine, ISSN 1078-8956, 06/2018, Volume 24, Issue 6, pp. 749 - 757
We describe results from IMmotion150, a randomized phase 2 study of atezolizumab (anti-PD-L1) alone or combined with bevacizumab (anti-VEGF) versus sunitinib... 
MEDICINE, RESEARCH & EXPERIMENTAL | MULTICENTER | PD-L1 EXPRESSION | BIOCHEMISTRY & MOLECULAR BIOLOGY | PHASE-III | SINGLE-ARM | CANCER | CELL BIOLOGY | PATHWAY | SUPPRESSOR-CELLS | NIVOLUMAB | TUMOR-GROWTH | ENDOTHELIAL GROWTH-FACTOR | Sunitinib - pharmacology | Bevacizumab - pharmacology | Kidney Neoplasms - genetics | Bevacizumab - therapeutic use | Bevacizumab - adverse effects | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Gene Expression Regulation, Neoplastic | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Carcinoma, Renal Cell - genetics | Antibodies, Monoclonal - therapeutic use | Male | Gene Expression Profiling | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Aged, 80 and over | Adult | Female | Carcinoma, Renal Cell - drug therapy | Antibodies, Monoclonal - pharmacology | Kaplan-Meier Estimate | Treatment Outcome | Mutation - genetics | Sunitinib - adverse effects | Sunitinib - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Kidney Neoplasms - drug therapy | Development and progression | Dosage and administration | Angiogenesis inhibitors | Carcinoma, Renal cell | Comparative analysis | Drug therapy | Cell survival | Inflammation | Gene expression | Molecular chains | Bevacizumab | Metastases | Confidence intervals | Angiogenesis | Immune checkpoint | Immunotherapy | γ-Interferon | PD-L1 protein | Biomarkers | Bioindicators | Vascular endothelial growth factor | Clear cell-type renal cell carcinoma | Index Medicus
Journal Article
Journal Article
International Journal of Dermatology, ISSN 0011-9059, 07/2019, Volume 58, Issue 7, pp. e138 - e140
Journal Article
Cancer Immunology, Immunotherapy, ISSN 0340-7004, 6/2013, Volume 62, Issue 6, pp. 1021 - 1028
Journal Article
Journal Article
Cancer Immunology, Immunotherapy, ISSN 0340-7004, 8/2009, Volume 58, Issue 8, pp. 1297 - 1306
Journal Article
by Maio, Michele and Lewis, Karl and Demidov, Lev and Mandalà, Mario and Bondarenko, Igor and Ascierto, Paolo A and Herbert, Christopher and Mackiewicz, Andrzej and Rutkowski, Piotr and Guminski, Alexander and Goodman, Grant R and Simmons, Brian and Ye, Chenglin and Yan, Yibing and Schadendorf, Dirk and Cinat, Gabriela and Fein, Luis Enrique and Brown, Michael and Guminski, Alexander and Haydon, Andrew and Khattak, Adnan and McNeil, Catriona and Parente, Phillip and Power, Jeremy and Roberts-Thomson, Rachel and Sandhu, Shahneen and Underhill, Craig and Varma, Suresh and Berger, Thomas and Awada, Ahmad and Blockx, Nathalie and Buyse, Veronique and Mebis, Jeroen and Franke, Fábio André and Jobim de Azevedo, Sérgio and Silva Lazaretti, Nicolas and Jamal, Rahima and Mihalcioiu, Catalin and Petrella, Teresa and Savage, Kerry and Song, Xinni and Wong, Ralph and Dabelic, Nina and Plestina, Stjepko and Vojnovic, Zeljko and Arenberger, Petr and Kocak, Ivo and Krajsova, Ivana and Kubala, Eugen and Melichar, Bohuslav and Vantuchova, Yvetta and Putnik, Kadri and Dreno, Brigitte and Dutriaux, Caroline and Grob, Jean-Jacques and Joly, Pascal and Lacour, Jean-Philippe and Meyer, Nicolas and Mortier, Laurent and Thomas, Luc and Fluck, Michael and Gambichler, Thilo and Hassel, Jessica and Hauschild, Axel and Schadendorf, Dirk and Donnellan, Paul and McCaffrey, John and Power, Derek and Ariad, Samuel and Bar-Sela, Gil and Hendler, Daniel and Ron, Ilan and Schachter, Jacob and Ascierto, Paolo and Berruti, Alfredo and Bianchi, Luca and Chiarion Sileni, Vanna and Cognetti, Francesco and Danielli, Riccardo and Di Giacomo, Anna Maria and Gianni, Luca and Goldhirsch, Aron and Guida, Michele and Maio, Michele and Mandalà, Mario and Marchetti, Paolo and Queirolo, Paola and Santoro, Armando and Kapiteijn, Ellen and Mackiewicz, Andrzej and Rutkowski, Piotr and Ferreira, Paula and Demidov, Lev and Gafton, Georgy and Makarova, Yulia and Andric, Zoran and Babovic, Nada and Jovanovic, Darjana and Kandolf Sekulovic, Lidija and Cohen, Graham and ... and BRIM8 Investigators
The Lancet Oncology, ISSN 1470-2045, 04/2018, Volume 19, Issue 4, pp. 510 - 520
Journal Article
Cancer Immunology, Immunotherapy, ISSN 0340-7004, 1/2012, Volume 61, Issue 1, pp. 41 - 48
Journal Article
Endocrine, ISSN 1355-008X, 12/2017, Volume 58, Issue 3, pp. 535 - 541
Ipilimumab is a human monoclonal antibody directed against cytotoxic T-lymphocyte antigen-4, that has been shown to significantly improve survival in patients... 
Medicine & Public Health | Science, Humanities and Social Sciences, multidisciplinary | Ipilimumab | Melanoma | Internal Medicine | CTLA-4 | Diabetes | Endocrinology | Hypophysitis | ANTIBODIES | ENDOCRINOLOGY & METABOLISM | INSIGHTS | Melanoma - complications | Pituitary Function Tests | Prevalence | Follow-Up Studies | Hypophysitis - diagnostic imaging | Humans | Middle Aged | Hypophysitis - epidemiology | Male | Antineoplastic Agents - therapeutic use | Ipilimumab - adverse effects | Hypophysitis - chemically induced | Magnetic Resonance Imaging | Antineoplastic Agents - adverse effects | Ipilimumab - therapeutic use | Melanoma - drug therapy | Age of Onset | Female | Aged | Prostatic Neoplasms - complications | Adrenocorticotropic Hormone - blood | Prostatic Neoplasms - drug therapy | Cohort Studies | Thyrotropin - blood | Antigens | Care and treatment | Pituitary hormones | Corticosteroids | Estrogen | Glycoproteins | Metastasis | T cells | Testosterone | Luteinizing hormone | Monoclonal antibodies | Prostate cancer | Headache | Clinical trials | Cytotoxicity | Lymphocytes T | Thyroid gland | Hydrocortisone | Estradiol | Metastases | Cell activation | Prolactin | Thyroid | Follicle-stimulating hormone | Cell survival | Secretion | Fatigue | Insulin | Adrenocorticotropic hormone | Magnetic resonance imaging | Pituitary | Growth hormone | Prostate | Index Medicus
Journal Article